Multi-target synergistic anti-aging composition as well as preparation method and application thereof

Abstract

The invention discloses a multi-target synergistic anti-aging composition and a preparation method and application thereof, the multi-target synergistic anti-aging composition comprises 0.065-1% by mass of an anti-aging reagent A: a narcissus bulb extract, glycerin and water; the anti-aging reagent B is prepared from a strawberry fruit extract, an astragalus membranaceus root extract, a vaccinium angustifolium fruit extract, PPG-13-decyl tetradecanol polyether-24, lecithin, 1, 3-propylene glycol and water in percentage by mass; the anti-aging reagent C is prepared from epigallocatechin gallyl glucoside and water, and the mass fraction of the epigallocatechin gallyl glucoside is 0.002-0.25%; and 0.5-2% by mass of an anti-aging reagent D: a bifidus yeast fermentation product lysate, glycerol and 1, 2-pentanediol. Four anti-aging reagents are adopted to cover four anti-aging paths of cell-level anti-aging, epigenetic regulation and control targets, mitochondria protection, mitochondria energy improvement and micro-ecological balance, and through the synergistic effect of the reagents, a'prevention-repair-maintenance 'integrated anti-aging system is realized, so that the daily skin anti-aging protection requirement is met.

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a multi-target synergistic anti-aging composition, a preparation method and an application thereof. Background Art

[0002] Skin aging is the result of the interweaving of multidimensional mechanisms such as gene regulation, oxidative damage, inflammatory cascade, and microecological imbalance. It is a complex multifactorial process involving the joint action of endogenous physiological mechanisms and exogenous environmental factors. Endogenous physiological mechanisms include telomere shortening, epigenetic disorders, mitochondrial dysfunction, etc. Exogenous environmental factors include ultraviolet radiation, environmental pollution and oxidative stress, lifestyle factors, etc.

[0003] Existing technologies struggle to achieve comprehensive anti-aging due to single-target interventions, unstable ingredients, or inefficient transdermal penetration. These include insufficient single-target interventions, which only improve a single aging symptom and result in low overall anti-aging efficacy; poor ingredient synergy; a lack of microecological regulation; and a failure to effectively integrate post-cosmetic repair with everyday anti-aging needs. These technologies struggle to address multiple aging factors, including photoaging, telomere shortening, mitochondrial damage, and chronic inflammation. Therefore, it is crucial to break through these limitations and provide a systematic, multi-factorial anti-aging solution. Summary of the Invention

[0004] In order to solve at least one of the above problems, the present invention provides a multi-target synergistic anti-aging composition, a preparation method and application thereof.

[0005] In order to achieve the above object, the present invention adopts the following technical means: The first aspect of the present invention provides a multi-target synergistic anti-aging composition comprising the following components in mass fractions: 0.065-1% anti-aging agent A, 0.1-1.5% anti-aging agent B, 0.002-0.25% anti-aging agent C, 0.5-2% anti-aging agent D, and the balance being water; Anti-aging agent A: Narcissus bulb extract, glycerin and water; Anti-aging agent B: strawberry fruit extract, astragalus membranaceus root extract, vaccinium angustifolia fruit extract, PPG-13-decyltetradeceth-24, lecithin, 1,3-propylene glycol, water; Anti-aging agent C: epigallocatechin galloside, water; Anti-aging reagent D: bifid yeast fermentation product lysate, glycerol, 1,2-pentanediol.

[0006] In some preferred embodiments of the present invention, anti-aging agent A: 0.9% narcissus bulb extract, 55% glycerin and 44.1% water; Anti-aging agent B: 5% strawberry fruit extract, 10% astragalus membranaceus root extract, 5% vaccinium angustifolia fruit extract, 22% PPG-13-decyltetradecyl alcohol polyether-24, 8% lecithin, 40% 1,3-propylene glycol, 10% water; Anti-aging agent C: 7.5% epigallocatechin galloside, 92.5% water; Anti-aging reagent D: 74.5% bifid yeast fermentation product lysate, 20% glycerol, 5.5% 1,2-pentanediol.

[0007] In some alternative embodiments of the present invention, the anti-aging agent A is an Astragalus extract.

[0008] In some alternative embodiments of the present invention, the anti-aging agent B is resveratrol.

[0009] In some alternative embodiments of the present invention, the anti-aging agent C is VC.

[0010] In some alternative embodiments of the present invention, the anti-aging agent D is olive leaf extract.

[0011] The second aspect of the present invention provides a method for preparing a multi-target synergistic anti-aging composition, comprising the following steps: S1. Clean and disinfect the necessary equipment, accurately weigh the raw materials of each component of the composition according to the formula of the first aspect to prepare anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D, and place them in clean and disinfected containers for later use; S2: Mix the anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D according to the proportions described in the first aspect, and stir until completely uniform; S3: Filter the material to obtain a multi-target synergistic anti-aging composition.

[0012] The third aspect of the present invention provides an application of a multi-target synergistic anti-aging composition in the preparation of cosmetics.

[0013] The fourth aspect of the present invention provides a daily chemical product comprising 0.1 to 10 wt % of the multi-target synergistic anti-aging composition of the first aspect.

[0014] In some embodiments of the present invention, preferably, the daily chemical product is an aqueous solution, a cream, an emulsion, or a spray.

[0015] In some embodiments of the present invention, preferably, the daily chemical product is a gel, essence, toner, facial mask, cleanser, sunscreen, primer, or liquid foundation.

[0016] Beneficial effects of the present invention Compared with the existing technology, the present invention has the following beneficial effects: the present invention adopts four anti-aging reagents, namely anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D, covering the four major anti-aging pathways of cellular-level anti-aging, epigenetic regulation targets, protection of mitochondria, and enhancement of mitochondrial energy and microecological balance. Through the synergistic effect of the four anti-aging reagents, an integrated anti-aging system of "prevention-repair-maintenance" is realized to meet the needs of daily anti-aging, medical beauty care and skin protection in special environments.

[0017] In the multi-target synergistic anti-aging composition, anti-aging agent A delays the proliferation of dermal fibroblasts, prompts aging fibroblasts to retain the "youthful" collagen precursor production capacity, maintains telomere length, and delays cell aging; combined with anti-aging agent B, it can inhibit SASP to improve skin aging, protect mitochondrial DNA from damage by ROS, activate the activity of the longevity gene SIRT1 to improve endothelial aging, enhance mitochondrial function, enhance cell homeostasis, reduce DNA damage to achieve anti-aging effects, reverse gene silencing through epigenetic regulation, restore cell youthfulness, and form a dual cellular-level anti-aging system.

[0018] Anti-aging agents B and C, respectively, inhibit ROS damage and protect mitochondrial function, strengthening mitochondrial health and DNA integrity. This synergistically protects mitochondria, delaying aging at the source of energy metabolism. Furthermore, Anti-aging agent C has certain efficacy against photoaging, post-cosmetics, and sun damage. Combined with the mitochondrial protection of Anti-aging agent B, this forms a comprehensive protection and repair network against external damage (such as UV rays and cosmetic trauma), achieving both repair and anti-aging benefits. Anti-aging agent D regulates the diversity of the skin microbiome, promoting its restoration and maintenance. This provides the skin with adequate nutrition, helps maintain a stable microenvironment, and inhibits chronic inflammatory aging induced by harmful bacteria, synergistically enhancing anti-aging effects from the perspective of skin barrier health. DETAILED DESCRIPTION

[0019] The following examples are provided to illustrate preferred embodiments of the present invention. Those skilled in the art will appreciate that the techniques disclosed in the following examples represent techniques discovered by the inventors that can be used to practice the present invention and, therefore, can be considered preferred embodiments of the present invention. However, those skilled in the art will appreciate from this disclosure that many modifications may be made to the specific embodiments disclosed herein while still achieving the same or similar results without departing from the spirit or scope of the present invention.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one skilled in the art to which this invention belongs, and the disclosures herein and the materials they cite are hereby incorporated by reference. Those skilled in the art will recognize or be able to ascertain, through routine experimentation, many technical equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the claims.

[0021] The technical solution of the present application will be further described in detail below in conjunction with specific implementation methods.

[0022] Anti-aging agent A: 0.9% Narcissus TAZETTA bulb extract, 55% glycerin, 44.1% water; The preparation method of narcissus bulb extract is as follows: crush the narcissus bulb until it can pass through a 45-mesh sieve, add water 8 times the weight of the narcissus bulb, soak at 45°C for 3 hours, heat to 70°C for extraction for 2 hours, combine the extracts, concentrate and dry to obtain the extract.

[0023] The narcissus bulb extract in anti-aging reagent A can regulate the activation of mTORC1, delay the proliferation of dermal fibroblasts, delay the cells from entering the aging stage, maintain telomere length, and achieve anti-aging effects at the cellular level.

[0024] The preparation method of the anti-aging reagent A is as follows: glycerol and water are added to the narcissus bulb extract, stirred evenly, and sterile filtered to obtain the product.

[0025] Anti-aging agent B: 5% strawberry (FRAGARIA CHILOENSIS) fruit extract, 10% Astragalus membranaceus root extract, 5% Vaccinium angustifolium (VACCINIUM ANGUSTIFOLIUM) fruit extract, 22% PPG-13-decyltetradecyl alcohol polyether-24, 8% lecithin, 40% 1,3-propylene glycol, 10% water.

[0026] The preparation method of strawberry fruit extract is as follows: crush the strawberry fruit, mix the strawberry fruit powder and the extraction solution with a pH value of 5 in a mass ratio of 1:11 at 38°C, stir for 4.5 hours, ultrasonicate at 1200 Hz for 30 minutes, filter through an 18-mesh filter, take the filtrate, concentrate the filtrate and spray-dry to obtain the strawberry fruit extract; the extraction solution is obtained by adding malic acid, citric acid and calcium chloride in a mass ratio of 3:4:1 to ethanol with a volume concentration of 80%.

[0027] The preparation method of the Astragalus membranaceus root extract is as follows: the Astragalus membranaceus root is crushed, the powdered Astragalus membranaceus root is taken, alkaline ionized water is added to the powdered Astragalus membranaceus root and shaken to obtain a mixed solution, the mixed solution is centrifuged to collect the centrifugal supernatant, and the obtained primary precipitate is then added with alkaline ionized water with a pH of 9.80-13.80 (produced by electrolysis of pure water, water enriched with hydroxide ions near the cathode is alkaline, i.e. alkaline ionized water, electrolysis potential: ≥-120mv) for secondary extraction, and the extraction is performed three times in sequence, and the three centrifugal supernatants are combined and concentrated to obtain the Astragalus membranaceus root extract.

[0028] The preparation method of the Vaccinium angustifolium fruit extract is as follows: washing and crushing the Vaccinium angustifolium fruit, adding 0.01-0.03% of cellulase based on the weight of the Vaccinium angustifolium fruit, mixing well, transferring the fruit to a fermentation room, fermenting at a temperature of 35-38°C and a humidity of 60-80%, fermenting at constant temperature and humidity for 24-48 hours, raising the temperature to 50-55°C, keeping the temperature for 8-10 hours, and then cooling to room temperature, transferring the material to a centrifuge, centrifuging to obtain an extract, and vacuum concentrating the extract to a relative density of 1.05-1.12 to obtain the Vaccinium angustifolium fruit extract.

[0029] Anti-aging agent B contains the active ingredients of fisetin, pterostilbene, and cycloastragenol, which improve skin aging by inhibiting SAAP and protect mitochondrial DNA from damage by ROS. It is also a protector of mitochondrial telomeres, and through epigenetic regulation targets, it reverses age-related gene silencing and restores cell youth.

[0030] The preparation method of anti-aging reagent B is as follows: strawberry (FRAGARIA CHILOENSIS) fruit extract, Astragalus membranaceus) root extract, narrow-leaved blueberry (VACCINIUM ANGUSTIFOLIUM) fruit extract, water, and 1,3-propylene glycol are stirred and dissolved at room temperature to obtain a mixed solution, which is filtered to obtain a filtrate, and the filtrate is mixed with PPG-13-decyltetradecyl alcohol polyether-24 and lecithin, heated to 60°C, and stirred and dissolved to obtain a mixed solution, and the mixed solution is homogenized under high pressure to obtain a preliminary solution, which is stirred, cooled, and tested to obtain the final product.

[0031] Anti-aging reagent C: 7.5% epigallocatechin galloside (EGCG CAS registration number: 989-51-5), 92.5% water.

[0032] EGCG in Anti-Aging Reagent C is a key active ingredient in green tea. It possesses potent antioxidant activity, neutralizing free radicals generated by external stimuli like UV rays and pollution. It protects the structural and functional integrity of mitochondrial membranes, thereby maintaining normal ATP synthesis and helping prevent wrinkles and photoaging. It also stimulates cell proliferation and differentiation, and through the collagen network, helps maintain skin elasticity. By protecting mitochondria, it is highly effective in treating photoaging, post-sun repair, and medical cosmetic procedures.

[0033] The preparation method of epigallocatechin galloside is as follows: epigallocatechin gallate and glucose are mixed, subjected to enzymatic glycosidation, enzyme denaturation and concentration under acidic conditions at 70°C, and sterile filtration to obtain the product.

[0034] Preparation method of anti-aging reagent C: epigallocatechin galloside and water are mixed uniformly in proportion to obtain the anti-aging reagent C.

[0035] Anti-aging reagent D: 74.5% bifid yeast fermentation product lysate (CAS registration number: 96507-89-0), 20% glycerol, 5.5% 1,2-pentanediol.

[0036] The lysate of the bifid yeast fermentation product in the anti-aging reagent D is fermented by bifidobacteria, which can regulate the diversity of the skin microbiome, inhibit chronic inflammatory aging induced by harmful bacteria, and maintain the balance of the skin's microecological flora.

[0037] The preparation method of anti-aging reagent D is as follows: Bifidobacterium adolescentis is inoculated and cultured to obtain a bacterial suspension, the bacterial suspension is amplified and cultured in a fermenter, and then the bacterial bodies are obtained by centrifugation. After the bacterial cell wall is broken, glycerol and 1,2-pentanediol are added, and the product is obtained by filtration.

[0038] The preparation method of astragalus extract is as follows: crush the astragalus, place the astragalus powder in a microwave extraction device, microwave power 500W, temperature 70 ° C, a total of three extractions, adding 70% ethanol for the first extraction, and extracting for 30 minutes; adding 70% ethanol for the second extraction, and extracting for 30 minutes; adding distilled water for the third extraction, and extracting for 40 minutes; the extract is placed in a suction filtration device for filtration, the second extract is concentrated, the ethanol is removed, and the third water extract is added, mixed, and concentrated to obtain the astragalus extract.

[0039] The preparation method of olive leaf extract comprises the following steps: removing impurities from olive leaves and crushing them, extracting the olive leaf powder with water at least twice to obtain an extract; wherein the extraction pressure is 0.15-0.25 MPa, the extraction temperature is 60-80°C, the extraction time is 1.5-2.5 hours each time, and the weight-to-volume ratio of the olive leaf powder to water is 1:10-1:20; concentrating the extract, precipitating with alcohol, and filtering to obtain a concentrated thick paste; and spray-drying the concentrated thick paste to obtain the olive leaf extract.

[0040] The preparation method of the multi-target synergistic anti-aging composition is as follows: prepare the components according to the ratio, mix and stir the raw materials until they are completely uniform, and filter the materials.

[0041] Example 1 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 1.5% anti-aging agent B, 0.25% anti-aging agent C, 1.5% anti-aging agent D, and the balance being water.

[0042] Example 2 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 0.5% anti-aging agent A, 1.5% anti-aging agent B, 0.2% anti-aging agent C, 1.0% anti-aging agent D, and the balance being water.

[0043] Example 3 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 0.8% anti-aging agent A, 0.5% anti-aging agent B, 0.05% anti-aging agent C, 0.8% anti-aging agent D, and the balance being water.

[0044] Example 4 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 0.2% anti-aging agent A, 1.0% anti-aging agent B, 0.25% anti-aging agent C, 0.5% anti-aging agent D, and the balance being water.

[0045] Comparative Example 1 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1.5% anti-aging agent B, 0.25% anti-aging agent C, 1.5% anti-aging agent D, and the balance being water.

[0046] Comparative Example 2 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 0.25% anti-aging agent C, 1.5% anti-aging agent D, and the balance being water.

[0047] Comparative Example 3 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 1.5% anti-aging agent B, 1.5% anti-aging agent D, and the balance being water.

[0048] Comparative Example 4 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 1.5% anti-aging agent B, 0.25% anti-aging agent C, and the balance being water.

[0049] Comparative Example 5 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% astragalus extract, 1.5% anti-aging agent B, 0.25% anti-aging agent C, 1.5% anti-aging agent D, and the balance being water.

[0050] Comparative Example 6 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 0.1% resveratrol, 0.25% anti-aging agent C, 1.5% anti-aging agent D, and the balance being water.

[0051] Comparative Example 7 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 1.5% anti-aging agent B, 0.25% VC, 1.5% anti-aging agent D, and the balance is water.

[0052] Comparative Example 8 A multi-target synergistic anti-aging composition comprises the following components in the following mass fractions: 1% anti-aging agent A, 1.5% anti-aging agent B, 0.25% anti-aging agent C, 1.5% olive leaf extract, and the balance water.

[0053] Effect verification: 1. Activity test of primary human dermal fibroblasts Experimental Methods: Primary human dermal fibroblasts were expanded and cultured in fibroblast culture medium under 5% CO₂ and 37°C. When the cells reached 80-90% confluence, they were trypsinized and seeded into 96-well plates. After the cells were adhered and cultured in the 96-well plates for 48 hours, the diluted compositions prepared in Examples 1 to 4 were used to treat the cells, forming Samples 1-4. Samples 1-4 were then used to treat the cells, yielding the sample groups corresponding to Examples 1-4. Simultaneously, the cells were treated with the same amount of deionized water as the sample groups, forming a control group.

[0054] After 48 hours, add CCK-8 reagent according to the instructions and incubate for 1 hour. Read the OD value at 450nm using a microplate reader. Calculate the relative cell viability value by calculating the ratio of the average OD value of the sample group to the control group to determine the cytotoxicity of the sample. The relative cell activity was calculated as follows: Relative cell activity% = (OD value of sample group / OD value of control group) * 100% The relative cell activity and SD test results of Examples 1 to 4 are shown in Table 1 below.

[0055] Table 1 Relative cell activity and SD test results of Examples 1 to 4

[0056] The results showed that the compositions prepared in Examples 1 to 4 had little effect on cell activity and had no cytotoxicity.

[0057] 2. Effects on collagen production in primary human dermal fibroblasts Experimental method: When the fibroblasts cultured in vitro grew to 80-90% confluence, they were digested with trypsin and seeded into 96-well plates. After the cells were attached and cultured in 96-well plates for 48 hours, the fibroblasts were starved overnight using a serum-free starvation medium to synchronize the growth of the cell population. Subsequently, the cells were treated with the different experimental group samples in Examples 1-4 and Comparative Examples 1-8 prepared with starvation medium, and a treatment group containing 100 μg / mL vitamin C was set as a positive control group. After 48 hours, the cell culture supernatant was used for ELISA testing of type I collagen. The measured collagen content of the experimental group and the positive control group was statistically compared with the untreated blank control group to evaluate the effect of the experimental group samples on the synthesis of type I collagen by dermal fibroblasts. The statistical results are shown in Table 2 below.

[0058] Table 2 Statistical results of the effects of each group of samples on the synthesis of type I collagen by dermal fibroblasts

[0059] The results showed that Examples 1-4 significantly promoted the production of type I collagen in fibroblasts, with Example 1 having the best promoting effect. Comparative Examples 1-8 also significantly promoted the production of type I collagen in fibroblasts, but the effects were weaker than those of Example 1.

[0060] 3. Telomere length test Experimental Methods: Cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C and 5% CO₂. When the cell density reached 80%-90%, they were digested and passaged using 0.25% trypsin. Samples from different experimental groups of Examples 1-4 and Comparative Examples 1-8 were added to the culture medium and pretreated for 24 hours. After pretreatment, cells were irradiated using a UVA light source (wavelength 365 nm) at an energy density of 5 J / cm² / day. PBS was replaced during irradiation to prevent phototoxic reactions. UVA irradiation was continued once daily for 3 days, and samples were processed. DNA was extracted and telomere length was measured using real-time quantitative PCR (qPCR).

[0061] The cells without sample pretreatment were directly irradiated with UVA as the UV irradiation group, and the cells without any treatment were set as the non-irradiation control group.

[0062] The results of telomere length detection in each group are shown in Table 3 below.

[0063] Table 3 Results of telomere length detection in each group

[0064] The results showed that the telomere length in Example 1 was significantly longer than that in the UV-irradiated group and even slightly longer than that in the non-irradiated control group. This treatment may not only completely reverse UV damage but also promote telomere length by activating telomerase or enhancing repair mechanisms. The telomere lengths in Examples 2-4 decreased in sequence, but remained significantly longer than those in the UV-irradiated group (p < 0.01), indicating that the protective effect gradually weakened with different concentrations, but all had a significant repair effect. The telomere lengths in Comparative Examples 1-8 were all significantly longer than those in the UV-irradiated group, but significantly lower than those in Examples 1-4. Example 1 demonstrated the best protection and repair effects, with telomere length restored to above the non-irradiated level (p < 0.01).

[0065] ATP production Human primary dermal fibroblasts were cultured in fibroblast medium at 5% CO2 and 37°C. When the cells reached 80-90% confluence, they were digested with trypsin and seeded into 96-well plates. The cells were treated overnight with samples from different experimental groups of Examples 1-4 and Comparative Examples 1-8, and then irradiated with UVA at 10 J / cm 2 After inducing cell damage, the samples were treated for 24 hours and the ATP production in each group was detected.

[0066] Setting not used UVA 10 J / cm 2 The damaged cells without sample treatment were used as blank control group and were irradiated with UVA 10 J / cm 2 The damaged cells without sample treatment were used as the UVA group.

[0067] The mean and SD results of the relative ATP content in each group are shown in Table 4 below.

[0068] Table 4 Mean and SD results of relative ATP content in each group

[0069] The results show that: it can be seen from Example 1 and Comparative Examples 1-4 that when anti-aging agent A, anti-aging agent B, anti-aging agent C, and anti-aging agent D are not added to Comparative Examples 1-4, the relative ATP contents of Comparative Examples 1-4 are 136.2%, 125.7%, 118.3%, and 127.7%, respectively. Based on the difference between the ATP content of Comparative Examples 1-4 and the UVA group, we can calculate that when anti-aging agent A, anti-aging agent B, anti-aging agent C, and anti-aging agent D are present at the same time, the theoretical value of ATP content should be approximately 136.0%, but the relative ATP content of Example 1 reached 164.7%. Therefore, we believe that a certain synergistic effect is generated between the anti-aging agent A, anti-aging agent B, anti-aging agent C, and anti-aging agent D, and Example 1 achieves a good effect exceeding the theoretical value of ATP content under the promotion of this synergistic effect.

[0070] It should be noted that in the above content, when anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D are present at the same time, the calculation method of the theoretical value of ATP content is: It is known that anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D exist at the same time, and the relative ATP content is 136.2%; When anti-aging reagent A, anti-aging reagent C, and anti-aging reagent D are present at the same time, the relative ATP content is 125.7%; When anti-aging reagent A, anti-aging reagent B, and anti-aging reagent D are present at the same time, the relative ATP content is 118.3%; When anti-aging reagent A, anti-aging reagent B, and anti-aging reagent C are present at the same time, the relative ATP content is 127.7%; And the relative ATP content of the UVA group was 100.0%; It can be inferred that the simultaneous presence of anti-aging reagents B, C, and D increased the relative ATP content by 36.2%. When anti-aging reagent A, anti-aging reagent C, and anti-aging reagent D were present at the same time, the relative ATP content increased by 25.7%; When anti-aging reagent A, anti-aging reagent B, and anti-aging reagent D were present at the same time, the relative ATP content increased by 18.3%; When anti-aging reagent A, anti-aging reagent B, and anti-aging reagent C were present at the same time, the relative ATP content increased by 27.7%; That is, 3 (anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, anti-aging reagent D) = 107.9%, so it can be concluded that when anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D exist at the same time, the theoretical value of the relative ATP content should be 136.0%.

[0071] 5. Test of release of inflammatory factors IL-6 and TNF-α Experimental method: Raw264.7 cells were cultured in DMEF high-glucose medium containing 10% FBS at 37°C and 5% CO2. Cells were passaged when they reached the logarithmic growth phase, and cells after at least three generations were used for the experiment. Raw264.7 cells in the logarithmic growth phase were digested with 0.25% trypsin and 0.02% EDTA for 2 minutes, then the trypsin was discarded and the trypsin was neutralized with 10% FBS DMEM medium. The cells were gently pipetted into a single-cell suspension, centrifuged and the supernatant was discarded. The cells were resuspended in complete medium and counted, and the cell suspension was adjusted to 8×10 5 / mL, 100 μL per well was inoculated into a 96-well plate, and the cells were cultured at 37°C and 5% CO2 for about 8 h to allow the cells to adhere to the wall. The supernatant from each well was aspirated, and 100 μL of serum-free DMEM medium was added to each well. The cells were randomly divided into a blank control group, an LPS group: LPS (1 μg / mL), an experimental group: LPS (1 μg / mL) was added, and samples from different experimental groups of Examples 1-4 and Comparative Examples 1-8 were cultured for 24 h at 37°C and 5% CO2. The inflammatory factors IL-6 and TNF-α were detected, and each group was measured 3 times to take the average value.

[0072] The mean and SD results of IL-6 content in each group are shown in Table 5 below.

[0073] Table 5 Mean and SD results of IL-6 content in each group

[0074] The mean and SD results of TNF-α content in each group are shown in Table 6 below.

[0075] Table 6 Mean and SD results of IL-6 content in each group

[0076] The results showed that the concentrations of IL-6 and TNF-α in Examples 1-4 ranged from 696-732 μg / mL and 671-726 μg / mL, respectively, which were approximately 62-65% and 60-64% lower than those in the LPS group, and the P values were significant (<0.0001), indicating that the treatment groups of Examples 1-4 were able to effectively inhibit the release of IL-6 and TNF-α induced by LPS, with Example 1 having the best effect. Comparative Examples 1-4 and Comparative Examples 5-8 were weaker than Example 1 in inhibiting the release of IL-6 and TNF-α induced by LPS, indicating that the expression ability of any of the anti-aging agents A, B, C, and D decreased to varying degrees after being missing or replaced. This shows that the anti-aging composition of the present application has a synergistic effect, and any component cannot be replaced.

[0077] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the present application.

Claims

1. A multi-target synergistic anti-aging composition, characterized in that: The invention comprises the following components in the following mass fractions: 0.065-1% of anti-aging agent A, 0.1-1.5% of anti-aging agent B, 0.002-0.25% of anti-aging agent C, 0.5-2% of anti-aging agent D, and the balance is water; Anti-aging agent A: Narcissus bulb extract, glycerin and water; Anti-aging agent B: strawberry fruit extract, astragalus membranaceus root extract, vaccinium angustifolia fruit extract, PPG-13-decyltetradeceth-24, lecithin, 1,3-propylene glycol, water; Anti-aging agent C: epigallocatechin galloside, water; Anti-aging reagent D: bifid yeast fermentation product lysate, glycerol, 1,2-pentanediol.

2. The multi-target synergistic anti-aging composition according to claim 1, characterized in that: The anti-aging agent A is astragalus extract.

3. The multi-target synergistic anti-aging composition according to claim 1, characterized in that: The anti-aging agent B is resveratrol.

4. The multi-target synergistic anti-aging composition according to claim 1, characterized in that: The anti-aging agent C is VC.

5. The multi-target synergistic anti-aging composition according to claim 1, characterized in that: The anti-aging agent D is olive leaf extract.

6. A method for preparing a multi-target synergistic anti-aging composition, characterized in that: The steps include: S1. Clean and disinfect the necessary equipment, accurately weigh the raw materials of each component of the composition according to the formula of any one of claims 1 to 5 to prepare anti-aging reagent A, anti-aging reagent B, anti-aging reagent C, and anti-aging reagent D, and place them in clean and disinfected containers for later use; S2: Mix the anti-aging agent A, the anti-aging agent B, the anti-aging agent C, and the anti-aging agent D according to the proportions described in claim 1, and stir until completely uniform; S3: Filter the material to obtain a multi-target synergistic anti-aging composition.

7. Use of the multi-target synergistic anti-aging composition according to any one of claims 1 to 5 in the preparation of cosmetics.

8. A daily chemical product, characterized in that: The invention comprises 0.1 to 10 wt % of the multi-target synergistic anti-aging composition according to any one of claims 1 to 5.

9. A daily chemical product according to claim 8, characterized in that: Daily chemical products include lotions, creams, emulsions and sprays.

10. A daily chemical product according to claim 8, characterized in that: The daily chemical products include gel, essence, toner, facial mask, cleanser, sunscreen, primer and liquid foundation.

Images